Seok Joo Lee – CEO, ISU Abxis, South Korea
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
Address: 15F, Haesung-2-building, Teheran-Ro 508, Gangnam-gu ,Seoul, Republic of Korea 135-725
Tel: +82-2-2185-3800
Web: http://www.merck.co.kr/en/index.html;jsessionid=BD027DF767B36C40BA9C1C74E6E903E9
Merck Republic of Korea, a Republic of Korean subsidiary of Merck KGaA Germany, a global research-driven pharmaceutical company dedicated to putting patients first; Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. Merck Republic of Korea Ltd. was founded in 1989 and established Merck Advanced Technologies Ltd. (MAT) in 2002 to better serve the Republic of Korean display industry. In the same year, an R&D and production center for liquid crystals and a warehouse were opened in Poseung.Earlier in 2009, Merck announced it is investing 14 billion Republic of Korean Won (? 11 million) to establish an Advanced Technology Center in Republic of Korea to improve it’s R&D and manufacturing capacities.
ISU Abxis, a subsidiary of the ISU conglomerate, is a biotech company with a focus on orphan drugs and rare disease. CEO Seok Joo Lee explains the rationale behind his…
Looking at what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. DHR International’s Helen Park outlines what she…
Syneos Health, established through a merger in 2017, has held a foothold in Korea through its legacy organisations for over 10 years. Sora Lee, general manager of Syneos Korea, provides…
SK Group, the second largest conglomerate in South Korea and renowned as a leader in energy, telecommunications, and the semiconductor business, entered drug development in 1993. In an exclusive interview,…
Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains…
Bioneer, founded in 1992, lays claim to be Korea’s oldest biotechnology company. President, founder and CEO, Dr Han-Oh Park introduces the technological advances they have developed in molecular research tools,…
The Korea Drug Development Fund (KDDF) is a government-funded organization created to accelerate innovation activities in the Korean life sciences sector. In this interview, Samuel Muk explains how he integrated…
Dr Nam Han Cho, president of the International Diabetes Federation (IDF) and professor of Preventive Medicine at the Ajou University School of Medicine in South Korea is taking stock of his…
This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and make a new, streamlined review process for advanced healthcare goods. The…
The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are…
Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry…
It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building…
See our Cookie Privacy Policy Here
